Novo Nordisk's pricing strategies in the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of selling price gouging, mentioning the stark contrast involving U.S. costs and people in Europe and copyright.In October 2024, Novo Nordisk posted a analyze on scientific journal Nature about a novel glucose-se